However, OS is not possible in prepubertal girls and may be contraindicated in women with estrogen receptor positive breast cancer, although FSH-induced hyperestradiolemia may be counteracted or avoided with adjuvant therapies like selective estrogen receptor modulators or aromatase inhibitors [83]. This evidence concerns the gene ESR1 and breast cancer.